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Abstract
Summary
Chronic morphine treatment alters gene expression in brain structures. There are increasing evidences showing a correlation, in gene
expression modulation, between blood cells and brain in psychological troubles. To test whether gene expression regulation in blood
cells could be found in drug addiction, we investigated gene expression profiles in peripheral blood mononuclear (PBMC) cells of
saline and morphine-treated rats. In rats chronically treated with morphine, the behavioural signs of spontaneous withdrawal were
observed and a withdrawal score was determined. This score enabled to select the time points at which the animals displayed the
mildest and strongest withdrawal signs (12h and 36h after the last injection). Oligonucleotide arrays were used to assess differential
gene expression in the PBMCs and quantitative real-time RT-PCR to validate the modulation of several candidate genes 12h and 36h
after the last injection. Among the 812 differentially expressed candidates, several genes (Adcy5, Htr2a) and pathways (Map kinases,
G-proteins, integrins) have already been described as modulated in the brain of morphine-treated rats. Sixteen out of the twenty four
tested candidates were validated at 12h, some of them showed a sustained modulation at 36h while for most of them the modulation
evolved as the withdrawal score increased. This study suggests similarities between the gene expression profile in PBMCs and brain
of morphine treated rats. Thus, the searching of correlations between the severity of the withdrawal and the PBMCs gene expression
pattern by transcriptional analysis of blood cells could be promising for the study of the mechanisms of addiction.
MESH Keywords        Analysis of Variance ; Animals ; Behavior, Animal ; drug effects ; Gene Expression Profiling ; Gene Expression Regulation ; drug effects ; Leukocytes,
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Introduction
Opiates are among the most largely used addictive drugs. Abused opiates primarily interact with  opioid receptors in the centralμ
nervous system and induce long-term behavioral and cellular alterations. A current challenge in opiate addiction is to understand the
molecular alterations underlying the adaptative changes observed. The structure of different classes of opioid receptors, the gene encoding
opioid receptors, and the signal transduction pathways triggered by opioids have been investigated extensively on neuronal cells in the last
fourth decades. Chronic morphine is associated with differential gene expression in several brain structures ( ; Ammon , 2003et al.
; ; ). Although some of the modifications observed in rodentBeitner-Johnson , 1992et al. Marie-Claire , 2004et al. McClung , 2005et al.
models of addiction could be found postmortem in the brain of opiate addicts ( , ; ), it isFerrer-Alcon , 2000et al. 2004 Albertson , 2006et al.
difficult to extrapolate all the results obtained from the animal brain to the patients.
Interestingly, in the case of several psychological and neurologic troubles including bipolar disorder, schizophrenia and Parkinson
disease, a correlation in gene expression modulation between blood cells and brain has been recently demonstrated ( ; Bowden , 2006et al.
). These results suggest that studies of the transcription level of certain genes in blood cells may give insights into theirDu , 2006et al.
modulation in the brain. Moreover, in the case of major depressive disorder studies of gene expression modulations showed that peripheral
leucocytes exhibit unique changes in the mRNA levels of several genes that are receptive to antidepressant treatment (Iga et al 2008).
Therefore, study of gene expression in peripheral blood mononuclear cells (PBMC) may be useful for a better understanding of brain and
neurological disease related pathways, and monitoring of therapeutic responses.
On immune cells, opioid receptors with similar pharmacological and biochemical characteristics to neuronal cells have been reported (
; ; ; ; ; ; ; Bidlack, 2000 Gaveriaux et al., 1995 McCarthy et al., 2001 Sharp et al., 1998 Sharp, 2006 Suzuki et al., 2001a Suzuki et al., 2001b
; ). Moreover, morphine has been shown to interfere with lymphocytic cells functions followingSuzuki et al., 2000 Wick et al., 1996
binding to these receptors ( ; ). Chronic morphine treatment has been shown to alter a number of immuneRahim , 2002et al. Roy , 2004et al.
parameters including phagocytosis ( ), antibody response in mice ( ) and cytokineEisenstein and Hilburger, 1998 Rahim , 2002et al.
production in human and mice peripheral blood mononuclear cells (PBMCs) ( ; ). Moreover,Pacifici , 2000et al. Peterson , 1989et al.
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morphine withdrawal has been shown to alter immune response in mice ( ; ). Gaveriaux-Ruff etBelcheva , 2002et al. Hilburger , 1997et al.
al showed morphine immunosuppressive effects during an escalating dose protocol in mice and these effects were abolished in
mu-receptor knockout animals ( ).Gaveriaux-Ruff , 1998et al.
In order to facilitate the interplay between morphine-treated rat models and opiate-dependent patients we chose to work on an easily
accessible tissue: PBMCs. To evaluate whether transcriptional profiling of PBMC could serve to identify genes regulated by morphine rats
were chronically treated with morphine during five days, and the behavioral signs of spontaneous withdrawal were observed at different
times after the last injection to select the time point at which the animals displayed the minimum withdrawal signs for subsequent analyses.
High-density oligonucleotide arrays were used to assess global differential gene expression in the PBMCs. The changes in gene expression
were also investigated for several transcripts by quantitative PCR 12h and 36h after the last injection when spontaneous withdrawal signs
were minimum and maximum respectively. The regulations of the selected genes were also studied 4h before the last injection in order to
estimate the influence of the withdrawal on the observed effects. The results showed that chronic morphine regulates gene expression in
PBMCs and interestingly among these genes several have previously been found modulated by morphine treatment in rat brain.
Materials and Methods
Animals and drugs
Male Sprague-Dawley rats (Janvier, Le Genest-Saint-Isle, France) weighing 180 250 g at the beginning of the experiments were–
housed four per cage. Animals were maintained under standard laboratory conditions (21 1 C, 55 60  relative humidity, 12h light/dark± ° – %
cycle, food and water ) for 3 to 5 days before the beginning of the experiments. Care and treatments of animals conformed to thead libitum
ethical standards and guidelines promulgated by the European Communities Council Directive (86/609/EEC). All efforts were made to
minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data. Morphine chlorhydrate
(Francopia, France) was dissolved in saline (0.9  NaCl). Morphine and saline solutions (0.1mL per 100 g of body weight) were injected%
intraperitoneally.
Animal Treatments
Dependence was induced in rats by repeated intraperitoneal injections of morphine twice daily at 08.00 AM and 19.00 PM. Morphine
doses were progressively increased from 10 to 40 mg kg  injection: first day 2 10 mg kg , second day 2 20 mg kg , third day 2 30 mg1− × 1− × 1− ×
kg , fourth and fifth days 2 40 mg kg . Control group was treated with saline following the same procedure.1− × 1−
Behavioral studies
Spontaneous withdrawal syndromes were observed for 15 min in circular plexiglass observation boxes (30 cm wide; 40 cm high) 12h,
18h and 36h after the last morphine injection. Two classes of withdrawal signs were measured: counted signs and observed signs. The
number of bouts of teeth chattering, wet dog shakes, mastication and tremor were counted and the sum is a score for each counted signs.
Ptosis, defecation, abnormal posture were observed over periods of 3 min, with one point being given for the presence of each sign during
each period. The number of periods showing the sign was then counted (maximum score 5). Global withdrawal score was calculated as the
sum of scores for all signs. Body weight was measured during the treatment and before observation period.
PBMC isolation and RNA extraction
PBMC isolation was carried out at 3 time-points: 4h before the last injection, 12h and 36h after the last injection on three independent
animal groups. Animals were anaesthetized using pentobarbital (100 mg kg ) at the mentioned time points and blood was collected by1−
intracardiac ponction (8 10 mL per animal). Rat PBMCs were isolated from whole blood by density gradient centrifugation on–
Ficoll-Paque Plus  lymphocyte separation medium (GE Healthcare Life Science, France). The layer with PBMCs was removed and®
washed twice with saline 0.9  and the recovered cells were used directly for total RNA extraction. Total RNA was isolated with Rneasy%
Micro Kits (Qiagen, Courtaboeuf, France), following the manufacturer s protocol. Each RNA sample was prepared from PBMCs’
individually isolated from one animal whole blood. Quantification of total RNA was assessed by spectrophotometry using a Nanodrop®
instrument (Nyxor, France).
Microarray target preparation and Affymetrix hybridization
The quality of the RNA samples was determined by electrophoresis using RNA labs chips (Agilent ). Synthesis of cDNA, synthesis®
and biotinylation of cRNA, fragmentation and hybridization were all performed according to the manufacturer s instructions (Affymetrix,’
Santa Clara, CA, USA) at the Affymetrix genopole facility (CHU Saint-Louis, Paris). Briefly, double-stranded cDNA was synthesized
from total RNA samples using a Superscript Choice Kit with a T7-dt24 primer incorporing a T7 RNA polymerase promoter. Biotinylated
cRNA was prepared by in vitro transcription using Enzo Bioarray High Yield RNA Transcript Labeling kit and then fragmented. The
fragmented and biotin-labeled cRNA samples were hybridized on Affymetrix  Rat Genome RAE230_2.0 Genechips (containing 31,000®
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probe sets) according to the manufacturer s instructions. Scanned images of the arrays were converted to numerical data by GCOS’
software (Affymetrix) and outputted to tab delimited text files containing Affymetrix  ProbeSet ID, signals, present or absent detection®
calls, and detection -values for each feature on the array. Comparison analyses were conducted using Dchip software 3.1 (P www.dchip.org
).
Microarray analysis
DNA-Chip analyzer (DChip) version 2006 ( ) was used to analyze Affymetrix data. A comparison between the fiveLi and Wong, 2001
hybridizations with morphine treatment and the five controls generated a change of P-value. The average percentage of probe sets that
were called as present was 60.7  among the different hybridizations except for one of the morphine array (53.5 ), this array was then% %
excluded from the subsequent study. Multiple comparisons of four morphine-treated against five control chips were therefore performed.
To identify potentially regulated transcripts we chose a cut-off of 50  fold change (treated vs.Control Assay Signal Ratio) and p<0.05.%
Results are displayed as mean of fold induction and/or reduction. The selected transcripts after the Dchip analysis were characterized using
NetAffix  Analysis center ( ) and FatiGO  ( ) ( ; ™ https://www.affymetrix.com + http://www.fatigo.org Al-Shahrour et al., 2006 Al-Shahrour et
). We used online tools that are specifically designed to assist investigators to classify the functional roles of the identifiedal., 2005
differentially expressed genes. The FatiGO  utilizes the Gene Ontology (GO) database provided by the GO consortium (+
) and other databases as KEGG pathway. We compared overexpressed or underexpressed gene lists with rathttp://www.geneontology.org/
RAE 230.2 array list. Then a Fisher s exact test was used to check for significant over representation of GO terms in one of the sets.’
Multiple test correction to account for the multiple hypothesis tested (one for each GO term) was applied (FDR adjusted test).
Reverse transcription and Real-Time PCR
Independent batches of RNA were obtained from PBMCs of morphine and saline-treated rats. Total RNAs were reverse transcribed in
a final volume of 20 L containing 1X RT-PCR buffer (Invitrogen , France), 500 M each deoxynucleotide triphosphate, 20 U of RNasinμ ® μ
RNase inhibitor (Promega, France), 10 mM DTT, 100 U of Superscript II RNase H  reverse transcriptase (Invitrogen, France), 1.5 M− μ
random hexamers (Amersham-Pharmacia , France), and 1 g of total RNA. Samples were incubated at 20 C for 10 min and 42 C for 30® μ ° °
min, and reverse transcriptase was inactivated by heating at 99 C for 5 min. PCR primers were chosen with the assistance of Oligo 6.42°
software (MedProbe, Norway). The primer nucleotide sequences used in this study are listed in . Fluorescent PCR analysis wasTable I
performed using a LightCycler  instrument (Roche Diagnostics, France). The cDNAs were diluted 40-fold and 5 L were added to the® μ
PCR reaction mix to yield a total volume of 10 L. The PCR reagents were obtained from the FastStart DNA Master SYBR Green I kitμ
(Roche Diagnostics, France). The reaction buffer contained 4 mM MgCl  and 0.5 M of each primer. Amplification protocols consisted of2 μ
35 40 cycles of denaturation at 94 C (5 s), annealing at 64 C (5 s), and extension at 72 C (10 s). cDNAs from a naive rat blood were used– ° ° °
to generate an external standard curve for each gene. We also quantified transcripts of the gene coding for the Ribosomal Protein Large, P0
(Rplp0), a component of the 60S subunit of ribosomes, as the endogenous RNA control and normalized each sample on the basis of its
RPLP0 content.
Statistical analysis
All series of data were analyzed with GraphPad Prism  4.0 software. For behavioral experiment, three independent experiments were®
performed, 15 morphine-treated rats and 15 control rats were compared at each time-point. Data were analyzed by two-way ANOVA with
Bonferonni post-test. For body weight study three independent experiments were performed, 28 treated and placebo rats were compared at
each time-point. Data were analyzed by two-way repeated measures ANOVA with Bonferonni post-test. For real-time quantitative
RT-PCR results, three additional experiments at 4h, 12h and 36h were carried out and the RNAs from 12 14 morphine-treated rats and− + + –
10 12 control rats were compared. Data were analyzed using Student s test between groups at each time point. Differences with <0.05– ’ p
between experimental groups at each point were considered statistically significant.
Results
Behavioral experiment
Physical dependence was induced in male Sprague-Dawley rats by repeated i.p injections of morphine twice daily and the withdrawal
signs were monitored in order to determine the time points for the transcriptional studies. The weight gain was monitored every 12h
throughout morphine treatment and withdrawal, as shown on . A significant increase of 18  was observed in control rats and thefigure 1a %
weight of rats treated with morphine increased by 13  during the five days of morphine treatment. This difference was not statistically%
significant. The weight of the control group continued to increase during 4 days after the last injection of saline; while morphine
withdrawal induced a significant reduction on weight gain in rats treated with the alkaloid. A maximum difference was observed in body
weights of control versus morphine-treated rats 36h after the last injection (p<0.001) ( ).Figure 1a
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Morphine-withdrawn animals showed behavioral signs of opiate withdrawal, including wet dog shakes, teeth chattering, diarrhea,
mastication, abnormal posture and ptosis. The calculated global withdrawal scores are presented in . Withdrawal signs werefigure 1b
observed at 12h, 18h and 36h after the last injection and global withdrawal scores of morphine-treated animals were significant (p<0.001)
at each time-point. Twelve hours after the last morphine injection, all the withdrawal signs were already present but the global withdrawal
score was less important than those calculated at 18h and 36h after the last injection. The 12h and 36h time points displaying the minimum
and maximum withdrawal scores were therefore selected for the subsequent studies.
Regulation of gene expression in the PBMCs
The Affymetrix GeneChip  Rat Genome RAE 230 2.0 was used to identify genes differentially regulated in the PBMCs of rats at ® +
12h after the last morphine injection. To obtain a set of differentially expressed genes and global gene expression profiling, we used a
combinaison of value (P<0.05) and fold change value (>1.5 or <0.66). Comparison of chronic morphine with control condition revealedP-
812 (596 up-regulated and 215 down-regulated) differentially expressed (50  fold or more) gene transcripts in PBMCs of treated rats. Of%
the 812 significantly modulated candidates, only 394 were annotated and represented 276 distinct genes, whereas the others (51.5 ) were%
transcripted loci with various levels of matches to known genes. A selective list of the genes modulated in this study is presented in Table
. We used NetAffix  Analysis Center and FatiGO  to identify the signalling pathways and genes families regulated by chronicII ™ +
morphine ( ). The results revealed several genes families that have been previously described as modulated by chronic morphine inFigure 2
the brain. We found that 7  of the 276 annoted genes regulated belong to the G-protein coupled receptor protein signalling pathway, these%
include G-protein coupled receptors and G-protein coupled protein. Signal transduction pathways were also represented such as mitogen
activated protein kinase pathway and cAMP pathway. Other regulated genes have a role in immunity and defense process interleukin 1
receptor, type I (Illr1), interferon beta 1 (Ifnb1), and a role in pro-apoptotic Tissue inhibitor of metalloproteinase 3 (Timp3), Bcl2
modifying factor (Bmf), guanine nucleotide binding protein, alpha q (Gnaq), NCK-associated protein 1 (Nckap1), and anti-apoptotic
pathways Sphingosine kinase 1 (Sphk1), Chemokine (C-C motif) ligand 2 (Ccl2), Fibroblast growth factor 8 (Fgf8) . Three[ ]
5-hydroxytryptamine receptors 6, 7 and 2a (Htr6, Htr7 and Htr2a), and calcium channels were also identified.
Validation of differentially regulated genes by quantitative RT-PCR at 12h
In order to validate the regulation of 24 selected genes we performed quantitative real-time RT-PCR on samples collected at the same
time-point (12h) as for the array analysis (minimum withdrawal). We chose genes of the G protein pathway (Gprk5, Gng11), genes of the
Mapk pathway (similar to mitogen-activated protein kinase kinase kinase kinase 5 isoform 2), mitogen-activated protein kinase 7 (Mapk7)
and genes known to be modulated in the brain by morphine treatment (Adcy5, Adenosine kinase, Htr2a). Since morphine promotes cells
apoptosis, we also chose to confirm the regulation of genes implicated in this process such as Bmf, Nckap1, Timp3, and also genes
implicated in cell adhesion such as Integrin beta 1 (Itgb1) and integrin alpha 6 (Itga6). Out of the 18 tested genes 12 were validated by
Q-RT-PCR ( ). Furthermore, the fold-changes obtained were similar to those calculated in the array experiments (  and Table III Table II
). We also tested 6 genes that belong to the tested families and almost fulfill the criteria detailed in the material and methodstable III
section: regulator of G-protein signalling 10 (Rgs10) (1.46), membrane interacting protein of Rgs16 (Mir16) (1.39), mitogen-activated
protein kinase 8 interacting protein 3 (Mapk8ip3) (1,35), adaptor-related protein complex 1, sigma 1 subunit (Ap1s1) (1.36), calpain 2
(Capn2) (1.4), RAS, guanyl releasing protein 2 (Rasgrp2) (1.22). We found that the regulations of Rgs10, Mir16, Capn2, Rasgrp2, were
verified by quantitative real-time RT-PCR at 12h ( ).Table III
Regulation of differentially regulated genes by quantitative RT-PCR at 36h
In order to compare the expression levels at the minimum and maximum withdrawal scores in our model, we carried out an additional
independent experiment at 36h to analyze the differential expression levels between morphine-treated and control rats of 18 genes
confirmed or not at 12h. Four groups of genes could be distinguished according to their pattern of regulation at 12h and 36h. Four genes+ +
(Adcy5, Mir 16, Camk4, and Anxa3) were significantly up-regulated at 12h but significantly down-regulated at 36h. A group with Itga6
and Rasgrp2 showed a sustained up-regulation at 12h and 36h. A group with Adk, Nckap1, Gng11, Gprk5, Rgs10, Capn2, Fgl2, Sod2,
Timp3, Ap1s1, and Itgb1 showed a significant up-regulation at 12h but no modulation at 36h. And a fourth group composed of Mapk8ip3
and Htr2A was not significantly modulated at 12h but significantly regulated at 36h.
Regulation of the validated genes during chronic morphine treatment
In order to know how the validated genes were being expressed before the onset of the withdrawal process, quantitative real time PCR
was performed on PBMCs of rat sacrificed on day 5. For all the tested genes the regulations observed 4h before the last morphine injection
confirmed those obtained 12 hours after the last morphine injection ( ). Furthermore, the fold changes observed at 4h were veryTable III −
similar to those obtained at 12h. In addition no significant regulation was found at 4h for the 7 genes that were not modulated at 12H.+ − +
Discussion
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The aim of this study was to identify differentially expressed genes in blood cells of morphine-dependent rats in spontaneous
withdrawal situation. The large majority of studies carried out to date have used opioid receptor antagonist-precipitated withdrawal
syndrome. However, this experimental approach greatly differs from the clinical setting where the opiate withdrawal syndrome occurs as a
result of drug intake cessation. To better mimic these conditions, spontaneous withdrawal was evaluated. We observed classical signs used
in behavioral studies and found low levels of withdrawal scores. Indeed spontaneous withdrawal induces milder behavioral modulation
than the naloxone-precipitated one. As expected, the severity of opiate withdrawal varied as a function of the time interval between the last
morphine administration and testing. In order to study the modifications in gene expressions in morphine-dependent rats and to minimize
the transcriptional effects of withdrawal, the 12h time point was selected for microarray analysis. At this time point, withdrawal+
symptoms and loss of weight were at their minimum. At 36h, the withdrawal signs were maximum, and this time point was therefore
selected for comparison with the 12h results. An additional time point (4h before the last injection) was chosen in order to assess the
modulation of the selected candidate genes before the beginning of the withdrawal process.
Several studies have demonstrated characteristic blood genomic profiles for different brain disorders and neurologic diseases (Du et al.
; ; ). A study of gene expression in PBMCs from schizophrenic patients suggested a correlation, 2006 Tang , 2005et al. Tang , 2004et al.
between the gene expression modulations patterns in PBMCs and the severity of the schizophrenic syndrome ( ). In theBowden , 2006et al.
case of migraine suffering patients differential gene expression modulations were found in platelets as compared to control patients (
). Tang and coworkers also found a specific gene expression pattern in PBMCs from Tourette syndrome patients (Hershey , 2004et al. Tang
). Moreover in the case of depression the low level of expression of alpha2a adrenergic receptors observed in the platelets of, 2005et al.
depressive patients could be increase after a treatment with an antidepressive compound ( ). These results suggestGarcia-Sevilla , 2004et al.
a correlation between the gene expression regulations in the brain and the blood cells in these pathologies. The identification of an easily
accessible tissue (blood) where modifications of gene expression following chronic morphine treatment could give insight to those
occurring in the CNS would facilitate clinical research on the mechanisms of addiction in humans ( ). In this study, weSullivan , 2006et al.
used PBMCs as a model to study blood expression profile following morphine treatment.
Our results describe the regulation of various genes and pathways in PBMCs of rats treated with morphine. 17 out the 24 tested genes
were validated by quantitative real-time PCR at 12h. Interestingly the modulations observed on the last day of the morphine treatment+
were similar to those obtained at the 12h time point of the spontaneous withdrawal but evolved as the withdrawal state worsens. Among+
the regulated pathways in PBMCs some have been previously identified in vitro in transcription studies. Stefano et al have showed a
regulation of apoptosis and cell adhesion genes in human peripheral blood leukocytes after acute morphine treatment ( ).Stefano , 2005et al.
In addition morphine has been shown to modulate immune responses ( ).Eisenstein and Hilburger, 1998
Interestingly, among the genes found regulated in PBMCs several have been previously reported to be involved in responses to
morphine in different brain regions. The two major transcription pathways (Mapk and G protein coupled receptor) reported to be regulated
by morphine treatment in brain ( ; ; ) were also found regulated in PBMCs.Asensio et al., 2006 Fan et al., 2002 Traynor and Neubig, 2005
Opioid receptor activations lead to physiological responses via coupling to inhibitory guanine nucleotide-binding regulatory protein (Gold 
), modulating several effectors, such as adenylyl cyclases, and voltage-gated Ca  channels. In the present study, modulations, 2003et al. 2+
of genes belonging to two major components of the development of opiate addiction were found in the PBMCs: the G-protein coupled
receptor signalling (Gprk5, gng11, Rgs 10, Mir 16) and the cAMP signalling (Adcy5) pathways. Adcy5 has been shown to play an
important role for the development of morphine behavioral effects ( ). Nestler et al have shown that decreased activation ofKim , 2006et al.
ERK1/2 might be relevant in modulating long lasting forms of synaptic plasticity in opiate addiction ( ). In the present studyNestler, 2001
we observed an increase in the expression of several mitogen-activated protein kinases (Mapk7, similar to Mapkkkk5). Mapk pathway has
been shown to be activated in various regions of rat brain by opioid receptors coupled to G-proteins ( ).Schulz , 2004et al.
Electrophysiological studies have suggested a functional relationship between the opioid and serotoninergic systems in the rat
prefrontal cortex involving the  and Htr2a receptors ( ). Moreover, an implication of Htr2a receptors in the dopamine release,μ Marek, 2003
locomotor response and behavioural sensitization to morphine has been demonstrated ( ). The present results showing aAuclair , 2004et al.
regulation of the serotonin receptor Htr2a by morphine treatment are consistent with these findings. Integrins are transmembrane receptors
allowing the interactions of cells with the extracellular matrix ( ). They are involved in several cellular functionsUings and Farrow, 2000
including the modulation of G-protein-coupled receptors signalling ( ). In this study we found that morphine treatmentBerg , 2007et al.
upregulated two integrins genes (Itgb1 and Itga6) in rat PBMCs. Moreover, the severity of the withdrawal symptoms did not affect the
expression of these two genes. Interestingly, Itgb1 has been recently shown to regulate opioid receptor signalling in sensory neurons (Berg 
)., 2007et al.
In conclusion, our data show that chronic morphine treatment induces transcriptional modifications in PBMCs that evolve with the
withdrawal state of the animals. This suggests that PBMC gene expression patterns could be indicative of the disease stage. For some of
the modulated genes the PBMC regulations confirmed previously reported brain modulations. In order to better characterize the
correlations suggested here, a study of the modulation of the differentially regulated genes obtained in PBMCs, in brain structures involved
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in addiction, is currently carried out. This approach could help to identify important diagnostic/prognostic markers as well as potential
therapeutic targets and mechanistic pathways.
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Figure 1
a) Evolution of weight variation as compared to weight before the first injection, n 15 rats per treatment. Body weight of each rat was=
measured before the injection (twice daily from 5 days) or the observation (from 12h to 96h after the last injection). Three independent+
experiments were achieved. Results are expressed as mean .SEM.  p<0.05, p<0.01,  p < 0.001, NS: non significant Two-way repeated± * ** ***
measure ANOVA. b) Evolution of global withdrawal score. Mean  SEM of opiate withdrawal score (n  15 rats per treatment) at 12h, 18h± = + +
and 36h after the last injection. Two Way ANOVA  p<0.05; p<0.01; p<0.001.+ * ** ***
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Figure 2
812 gene transcripts were identified, 596 up-regulated and 215 down-regulated genes under morphine treatment. Only 276 were identified as
distinct gene. Data were presented according to Gene ontology classification of the biological processes most frequently involved by the 276
genes. The percentage distribution of up- and down-regulated genes with GO annotation in each category of biological process was shown.
Each asterisk ( ) represent a significant differential regulation in the category compared (p<0.05 by Fisher).*
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Table I
Primer sequences used for SYBR Green-based real-time quantitative polymerase chain reaction.
Gene gene forward primer (sense) gene reverse primer (antisense)
Adcy5 5  ATGGGTCTGCTTTTCCACT 3′ ′ 5  GGAGGTGTGAGGAGAGAATG 3′ ′
Adk 5  TGAGCGTTCCTGCCTTGA 3′ ′ 5  CCCTCTACGGTAATAATG 3′ ′
Anxa3 5  CTGTGGAGGAGATGATTGAAGA 3′ ′ 5  TCGTACAGCACTCCAGCA 3′ ′
Ap1s1 5  CTCCAGCCCTACATACAAAC 3′ ′ 5  CCCTAAAGCCTTCAGTGG 3′ ′
Bmf 5  GAGCCAAGTAGTCAGTTACCAC 3′ ′ 5  GTCCAATCCAGTCCAGTCAT 3′ ′
Camk4 5  CATCCTACACCCTCCACAAGTCT 3′ ′ 5  ACAAGGCTGGTCCCCCTC 3′ ′
Capn2 5  CAGCAAGCCCTCTTAGACT 3′ ′ 5  TCTGAGCCCTGTTCTCC 3′ ′
Fgl2 5  TATCGCTTTTTGGCTGAACA 3′ ′ 5  AGAGGCTGAAGACATTTGCT 3′ ′
Gng11 5  TCCAGAAGACAAGAATCCC 3′ ′ 5  ATTTCCCTCCAGAGTTCCT 3′ ′
Gprk5 5  ACTTGGAAGCAGAACTTGTAAC 3′ ′ 5  TGGGGGAACAGTATCCTATC 3′ ′
Htr2a 5  CAGGCGAGTCACAGGATAG 3′ ′ 5  CACAGCAGTAAAAGACAGCA 3′ ′
Itga6 5  GAAGTGAGGACCCTTGCTGATG 3′ ′ 5  CGAACCTGTGCCTTAGTGACAA 3′ ′
Itgb1 5  AAAGCAAATGCCAAATCTTGTG 3′ ′ 5  TTCCTTCTTGTAAAAATGTCGTA 3′ ′
Mapk7 5  CCCGCTGACATTGAGTCT 3′ ′ 5  GTGGGTCTCAGGGTTCTTG 3′ ′
Mapk8ip3 5  TGGAGAGCAACTGACAAGA 3′ ′ 5  AGTGCCCCTGAAGAGTAAG 3′ ′
Mir16 5  AAAGGAATCCAGGTTGTTAGTT 3′ ′ 5  CAAGGTGGGACTCGTAGTAAT 3′ ′
Nckap1 5  GGAAGCAGACTCAGTTTCTC 3′ ′ 5  CAGCAGGGTCCAAGGTAG 3′ ′
Ptpn22_predicted 5  CAAGCAAGCCTACAGAATG 3′ ′ 5  TGGTCCTTTGGGTTTTG 3′ ′
Ralgps2 5  GAAGGCAAAAAACCCACAGT 3′ ′ 5  CCACCACAGACACATTCTTA 3′ ′
Rasgrp2 predicted 5  GAAGCCTTTGATGACTCTGG 3′ ′ 5  GGGATTGCTGATAGAAGTGG 3′ ′
similar to Mapkkkk5 isoform 2 5  CTCACAGCAATCTCTACATCC 3′ ′ 5  CATTCGTCGTCTTGTCACT 3′ ′
Rgs10 5  GGCGGACTGAGGAAGAG 3′ ′ 5  CACAACAAAGCAATGACATC 3′ ′
RPLP0 5  GGGGCCACCTGGAGAACAAC 3′ ′ 5  GCA GCA GCT GGC ACC TTA TTG 3′ ′
SOD2 5  GGCTTGGCTTCAATAAGGAG 3′ ′ 5  ATCCCCAGCAGTGGAATA 3′ ′
Timp3 5  GAAGCCTCTGAAAGTCTCTG 3′ ′ 5  CCCACCTCTCCACAAAGT 3′ ′
Table II
Affymetrix data at 12h of selective genes. Fold changes compare PBMC s treated rats to PBMC s saline rats. In bracket, fold change of different probe sets on the array’ ’
Accession Full name of gene gene
F o l d
Change Accession Full name of gene gene
Fold
change
Signal transduction Integrin-mediated signalling pathway
NM_022600 Adenylate cyclase 5 Adcy5 2.69 AI137931 Integrin, alpha 6 Itga6 1.89
NM_012823 Annexin A3 Anxa3 0.34 BF418243 Integrin alpha V (predicted) Itgav predicted 1.65
M63334 Calcium/calmodulin-dependent protein kinase IV Camk4 2.69 NM_017022 Integrin beta 1 (fibronectin receptor beta) Itgb1 1.83
AJ005424 Mitogen-activated protein kinase 7 Mapk7 0.66 NM_012587 Integrin binding sialoprotein Ibsp 2.3
BM387133 Ral GEF with PH domain and SH3 binding motif 2 Ralgps2 0.64 Metabolism
AI102560 Rap guanine nucleotide exchange factor (GEF) 5 Rapgef5 0.49 NM_012786 Cytochrom c oxidase subunit VIII-H Cox8h 0.47
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(heart/muscle)
BI279720 RAS-like, family 12 (predicted) Rasl12 predicted 0.64 M58041 Cytochrome P450, family 2, subfamily c,
polypeptide 70
Cyp2c70 0.33
AI577569 RAS protein-specific guanine nucleotide-releasing factor 1 Rasgrf1 3.97 NM_031509 Glutathione S-transferase A3 Gsta3 2.57
AA945062 Rho GTPase activating protein 8 Arhgap8 0.38 NM_012796 Glutathione S-transferase, theta 2 Gstt2 1.61
BF396580 Rho GTPase activating protein 5 similar to mitogen-activated Arhgap5 Similar 0.39 U48220 Cytochrome P450, family 2, subfamily d,
polypeptide 22
Cyp2d22 1.88
BI291366 protein kinase kinase kinase kinase 5 isoform 2 (predicted) Mapkkkk5
isoform 2
2.23 Cell differenciation
G-protein coupled receptor protein signaling pathway NM_019242 Interferon-related developmental regulator 1 Ifrd1 1.55
NM_017254 5-hydroxytryptamine (serotonin) receptor 2A Htr2a 1.74 NM_012731 Neurotrophic tyrosine kinase, receptor, type 2 Ntrk2 1.62
L03202 5-hydroxytryptamine (serotonin) receptor 6 Htr6 0.64 AB049572 sphingosine kinase 1 Sphk1 1.73
X69663 5-hydroxytryptamine (serotonin) receptor 7 Htr7 1.67 Inflammatory
BG379920 Adenosine A3 receptor Eaf2/Adora3 1.6 NM_013123 Interleukin 1 receptor, type 1 II1r1 1.78
NM_012768 Dopamine receptor D5 Drd5 1.8 Transcription
AI012890 G protein-coupled receptor 43 Gpr43 2.5 BE096021 Jun D proto-oncogene Jund 4.5
BF404188 G protein-coupled receptor 137B (predicted) Gpr137b 2.01 BG666291 Kruppel-like factor 7 (ubiquitous) (predicted) Klf7 predicted 2.2
NM_030829 G protein-coupled receptor kinase 5 Gprk5 2.08 Immune response
NM_022396 Guanine nucleotide binding protein (G protein), gamma 11 Gng11 1.57 BF403233 RT1 class Ib, locus M3 RT1-M3 2.31
NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 1.67 BI292055 RT1 class Ib, locus Aw2 RT1-Aw2 0.45
BE117491 Guanine nucleotide binding protein, alpha q polypeptide Gnaq 1.54 NM_031530 chemokine (C C motif) ligand 2– Ccl2 0.18
BI293698 HtrA serine peptidase 3 (predicted) Htra3 predicted 0.56 Others functions
NM_022800 purinergic receptor P2Y, G-protein coupled 12 P2ry12 2.77 BI298352 Adaptor-related protein complex 3, beta 2 subunit
(predicted)
Ap3b2
predicted
2.83
Transport U90340 Adenosine kinase Adk 1.82
NM_031760 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Abcb11 1.54 NM_017135 Adenylate kinase 3-like 1 Ak3l1 1.92
NM_080582 ATP-binding cassette, sub-family B (MDR/TAP), member 6 Abcb6 1.77 NM_031518 Cd200 antigen Cd200 0.37
Apoptosis BF565278 DnaJ (Hsp40) homolog, subfamily A, member 4 Dnaja4 2.01
NM_139258 Bcl2 modifying factor Bmf 1.93 BF404861 DnaJ (HSP40) homolog, subfamily C, member 14 Dnajc14 0.43
NM_019127 interferon beta 1, fibroblast Ifnb1 0.51 AF323608 Fibrinogen-like 2 Fgl2 1.85
BM383722 NCK-associated protein 1 Nckap1 2.55 NM_133286 fibroblast growth factor 8 Fgf8 2.38
AI009159 Tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
Timp3 2.93 BE107694 G protein-coupled receptor kinase-interactor2 Git2 1.64
Calcium ion transport BF404562 Gamma-aminobutyric acid A receptor, gamma 2 Gabrg2 1.89
AF361341 Calcium channel, voltage-dependent, gamma subunit 4 Cacng4 1.62 AF090113 Glutamate receptor interacting protein 2 Grip2 2.39
AF394940 Calcium channel, voltage-dependent, L type, alpha 1C subunit Cacna1c 0.66 BM391206 Histone 1, H2bh Hist1h2bh 1.59
AF290212 Calcium channel, voltage-dependent, T type, alpha 1G subunit Cacna1g 2.3 X00336 Interferon-alpha 1 Ifna1 0.58
NM_031601 Calcium channel, voltage-dependent, T type, alpha 1H subunit Cacna1h 1.83 NM_012983 Myosin ID Myo1d 2.91
Cell adhesion AI045505 Myosin X (predicted) Myo10
predicted
0.5
NM_022184 Calcium/calmodulin-dependent serine protein kinase (MAGUK family) Cask 0.58 NM_012604 myosin, heavy polypeptide 3, skeletal muscle,
embryonic
Myh3 1.87
AF065147 CD44 antigen Cd44 1.54 NM_013194 myosin, heavy polypeptide 9, non-muscle Myh9 1.58
AI227627 CD9 antigen Cd9 1.6 AA963282 Nicotinamide nucleotide adenylyltransferase 3 Nmnat3 1.65
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NM_031699 Claudin 1 Cldn1 2.14 AA955815 Ribosomal protein S6 kinase, polypeptide 5
(predicted)
Rps6ka5
predicted
Blood coagulation BG671549 Superoxide dismutase 2, mitochondrial Sod2 2.11
NM_022924 Coagulation factor II F2 0.49
NM_021698 Coagulation factor XIII, A1 subunit F13a1 2.35
Table III
Validation and evolution of differentially regulated genes by quantitative RT-PCR at 4h, 12h and 36h of the last morphine injection. Data represent fold change in PBMCs of morphine treated rat (n− + + =
12 14) as compared to saline treated rats (n 10 12).– = –
Gene −4H +12H +36H
Adcy5 1.93*** ↗ 2* ↗ 0.39** ↘
Anxa3 nd 1.88* ↗ 0.5** ↘
Camk4 1.24* ↗ 1.38* ↗ 0.75* ↘
Mir16 1.37** ↗ 1.39*** ↗ 0.74* ↘
Rasgrp2 1.16* ↗ 1.22* ↗ 1.27* ↗
Itga6 1.84*** ↗ 1.6** ↗ 1.81* ↗
Adk 1.58** ↗ 1.67** ↗ 1.1 –
Capn2 1.52** ↗ 1.4* ↗ 0.98 –
Fgl2 1.95** ↗ 1.6* ↗ 1.01 –
Gng11 2.22* ↗ 2.17** ↗ 0.98 –
Gprk5 2.43*** ↗ 1.56* ↗ 1.01 –
Itgb1 1.69** ↗ 1.59** ↗ 0.98 –
Nckap1 2.57* ↗ 1.69* ↗ 0.98 –
Rgs10 1.5** ↗ 1.46** ↗ 0.97 –
Sod2 2** ↗ 2.44** ↗ 1.02 –
Timp3 2.97** ↗ 2.14** ↗ 1.09 –
Ap1s1 1.18* ↗ 1.36* ↗ 0.97 –
mapk8ip3 1.21 – 1.18 – 0.64* ↘
Htr2a nd 1.38 – 0.46** ↘
Ralgps2 1.02 – 1.22 – 0.29 –
Bmf 0.83 – 0.19 – nd
Mapk7 1.13 – 0.38 – nd
Ptpn22 predicted 1.08 – 1 – nd
similar to Mapkkkk5 isoform 2 0.97 – 0.63 – nd
Statistical analysis was done by Student test
 
* p<0.05,
 
** p<0.01,
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** p<0.01,
 
*** p<0.001 as compared to control group.
